ArticleBMC public health2025
Global burden, socioeconomic disparities, and spatiotemporal dynamics of opioid use disorder mortality and disability: a comprehensive analysis from the global burden of disease study 2017-2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Community-level determinants of buprenorphine provider availability: A ZCTA-level (zip code tabulation area) analysis.Drug and alcohol dependence reports · 2026Article
- Examining the effects of pill counts on treatment retention in buprenorphine maintenance therapy.Drug and alcohol dependence reports · 2026Article
- Unemployment & opioid use disorder - socio-medical assessment results by the Medical Service of the German Federal Employment Agency.Substance abuse treatment, prevention, and policy · 2026Article
- Buprenorphine Oral Lyophilisate for Treatment of Opioid Use Disorder: Pharmacology and Clinical Efficacy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Burden of Infectious Diseases in Afghanistan in 1999 and 2023: Findings From the Global Burden of Disease 2023 Study.Cureus · 2026Article
- Trend analysis and future projections of global burden of opioid use disorder (OUD) from 1990 to 2030.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe escalating global burden of opioid use disorder (OUD) necessitates a nuanced understanding of its epidemiological patterns, socioeconomic determinants, and temporal trends. This study quantifies the global, regional, and national burden of OUD-related mortality and disability, evaluates policy correlates, and identifies critical disparities across demographic and socioeconomic strata.
methodsUsing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017–2021, we analyzed age-standardized mortality rates (ASMRs), disability-adjusted life years (DALYs), and their 95% uncertainty intervals (UIs) across 204 countries and territories. Joinpoint regression modeled temporal trends, while multivariable generalized estimating equations (GEEs) assessed socioeconomic gradients via the Socio-demographic Index (SDI). Geospatial clustering was evaluated using Moran’s I statistic. Robustness was confirmed through sensitivity analyses, counterfactual modeling, and cross-validation.
resultsGlobally, OUD mortality increased by 12.4% between 2017 and 2021, with the Americas remaining the epicenter (ASMR: 5.72 per 100,000; +47.3% deaths). Europe demonstrated progress (mortality decline: -1.8%), while Asia and Africa faced rising chronic disability (DALYs: +3.0% and + 10.2%, respectively). National-level extremes ranged from 0.01 per 100,000 in Japan to 7.16 per 100,000 in Canada. A pronounced socioeconomic gradient emerged: high-SDI regions exhibited 17.8-fold higher mortality rates (0.641% vs. 0.036% in low-SDI regions) and 13.9-fold greater DALY rates. Sex disparities persisted (male-to-female mortality ratio: 4.7:1), with males experiencing biphasic trends (+ 3.8% annual percent change [APC] pre-2020, -6.5% post-2020). Geospatial analyses revealed diverging trajectories, including rising mortality in the Americas (+ 4.2% APC) and declines in Africa (-3.1% APC).
conclusionThis study highlights stark regional and socioeconomic disparities in the OUD burden, exacerbated by synthetic opioid proliferation in high-income settings and chronic disability in resource-limited regions. Evidence-based harm reduction policies in high-SDI nations mitigated disability, while low-SDI regions faced accelerating crises. Targeted interventions addressing socioeconomic inequities, gender-specific risks, and geospatial vulnerabilities are urgently needed to curb the global opioid epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.